However, genetic mutations in CRC such as Kirsten RAS (KRAS), TP53 or mismatch repair (MMR) genes allow for replication errors and instability, making CRC an ideal cancer for CHK1 inhibition. The gene discussed is KRAS; the disease is colorectal carcinoma.